Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Featured Content from MarketBeat.com
3 Ways to Invest in the Growing GLP-1 Weight Loss MarketBy Nathan Reiff. Date Posted: 4/17/2026. 
Key Points
- The GLP-1 agonist market could triple in the coming years, and a number of new players are attempting to gain access to the space with novel drugs in development.
- Structure Therapeutics may warrant a closer look from investors, as its GLP-1 agonist candidate has shown promising trial results.
- It's also now possible to gain diversified exposure to the market via ETFs like OZEM and THNR, the former of which in particular has performed well in the last year.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Weight‑loss drugs are big business, with the GLP‑1 receptor agonist market expected to nearly triple to $185 billion by 2033—a compound annual growth rate of about 12.4%. Although this is increasingly a global medical phenomenon, the bulk of the market still exists in the United States, and domestic investors can gain exposure by targeting companies that manufacture these therapies. It would be a mistake to assume all GLP‑1 sales will be limited to major products like Ozempic or Wegovy, both produced by pharma giant Novo Nordisk A/S (NYSE: NVO). Demand in this relatively new space is so strong that a growing number of alternatives are rapidly emerging despite the apparent dominance of a few large players. Below, we highlight a lesser‑known biotech with a promising alternative in development and two exchange‑traded funds (ETFs) that offer broader, diversified exposure to the industry. A Pivot Toward GLP‑1 Drugs Could Be Transformational for Structure Therapeutics
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itself - it's the infrastructure behind it.
One small-cap company supplies a mission-critical component to Musk's xAI Colossus site that can't be built around. While retail waits for a ticker that doesn't exist yet, early money is moving into this supplier at a fraction of its potential value. See the small-cap stock powering the SpaceX buildout today
Structure Therapeutics (NASDAQ: GPCR) is a biotechnology company developing drugs that target G protein‑coupled receptors (GPCRs). The firm has traditionally pursued treatments for metabolic and inflammatory diseases such as fibrosis and nonalcoholic steatohepatitis. More recently, Structure has followed the trend toward GLP‑1 therapies. Its candidate aleniglipron has demonstrated about 16.3% weight loss in trials (adjusted for certain factors) and could compete favorably with peers on safety and manufacturing costs. Although Structure is not yet profitable, it holds roughly $1.4 billion in cash, providing runway over the coming quarters as aleniglipron advances toward a pivotal Phase 3 trial. Analysts have noted Structure's potential based on aleniglipron's prospects: 15 of 18 analyst ratings are Buy or equivalent. Shares have fallen about 20% year‑to‑date amid broader headwinds, but with a consensus price target of $110, Structure's stock could more than double from current levels. The First GLP‑1 Agonist ETF Is Building a Track Record of SuccessThere is significant investor interest in the GLP‑1 space, reflected by a growing number of ETFs dedicated to the theme. The Roundhill GLP‑1 & Weight Loss ETF (NASDAQ: OZEM) was an early entrant, launching in mid‑2024. The actively managed fund focuses on roughly two dozen pharmaceutical companies positioned to benefit from the growth of the GLP‑1 agonist industry. Novo Nordisk and rival Eli Lilly & Co. (NYSE: LLY) are prominent holdings, together accounting for nearly 30% of the portfolio. The fund's basket is geographically diverse, including both domestic and international names. Importantly, OZEM provides exposure not only to large companies that produce or sell GLP‑1 therapeutics but also to firms developing other weight‑loss enablers and to businesses supporting the supply chain critical to production. As an actively managed ETF, OZEM carries an expense ratio of 0.59%. While higher than many passive ETFs, that fee is competitive versus other actively managed funds. The niche fund has about $52 million in assets and modest trading volume, yet it has returned roughly 45% over the past year, rewarding long‑term holders. A modest dividend is an additional perk. Another GLP‑1 ETF With a Passive ApproachAn alternative in this ETF niche is the Amplify Weight Loss Drug & Treatment ETF (NYSEARCA: THNR). THNR is similar to OZEM in several respects: it charges an annual fee of 0.59% and contains roughly two dozen pharmaceutical names tied to the GLP‑1 agonist market. It also places significant weight on Novo Nordisk and Eli Lilly, though those two make up about a quarter of the portfolio—leaving more room for other companies. A key difference is that THNR is passive: it tracks an index of companies in the GLP‑1 industry, with weightings determined by float‑adjusted market capitalization and other factors such as trading volume. The index is rebalanced quarterly, which some investors may prefer as a straightforward, market‑reflective approach compared with active management. However, THNR's asset base is small—around $4 million—and its trading volume is similarly low. The fund has returned roughly 30% over the past year, a solid performance but notably below OZEM's recent gains. |
Post a Comment
Post a Comment